SAB Biotherapeutics (SABS) Capital Leases (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Capital Leases data on file, last reported at $3.1 million in Q1 2026.

• Quarterly Capital Leases fell 4.85% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 4.85% YoY) and the FY2025 annual result came in at $3.1 million, down 4.7% from the prior year.
• Capital Leases retreated to $3.1 million in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $3.7 million in Q1 2022 to a low of $3.1 million in Q1 2026.
• A 5-year average of $3.4 million and a median of $3.4 million in 2024 frame the typical range for Capital Leases.
• Annual changes were most pronounced in 2022 — Capital Leases declined 3.53% — and 2024, when it retreated 5.9%.
• Tracing SABS's Capital Leases over 5 years: stood at $3.6 million in 2022, then fell by 5.82% to $3.4 million in 2023, then decreased by 4.17% to $3.3 million in 2024, then slipped by 4.7% to $3.1 million in 2025, then declined by 1.29% to $3.1 million in 2026.
• The last three Capital Leases figures came in at $3.1 million (Q1 2026), $3.1 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.